UroGen Pharma Ltd. (URGN) Q2 FY26 Earnings Call

Sisteri’s $50.4 million Q2 revenue and 73% sequential growth are the call’s strongest signal. [3]

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-05
Length50 minutes
EPS$-0.28
EPS consensus$-0.38
Revenue$72.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All URGN earnings · Back to URGN overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.